Recent progress in synthetic self-adjuvanting vaccine development.
Biomater Sci
; 10(15): 4037-4057, 2022 Jul 26.
Article
in English
| MEDLINE | ID: covidwho-1900676
ABSTRACT
Vaccination is a proven way to protect individuals against many infectious diseases, as currently highlighted in the global COVID-19 pandemic. Peptides- or small molecule antigen-based vaccination offer advantages over the classical vaccine approaches. However, peptides or small molecules by themselves are generally not sufficiently immunogenic, and thus require an adjuvant to boost an immune response. Several conjugated systems have been developed in recent years to overcome this obstacle. This review summarises different moieties which, when conjugated to peptide antigens, facilitate a specific immune response. Different classes of self-adjuvant moieties are reviewed, including self-assembly peptides, lipids, glycolipids, and polymers.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Vaccine Development
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Biomater Sci
Year:
2022
Document Type:
Article
Affiliation country:
D2bm00061j
Similar
MEDLINE
...
LILACS
LIS